MK-677 (Ibutamoren)

Mechanism

A pill you take by mouth that mimics the hunger hormone ghrelin, tricking your pituitary gland into releasing more growth hormone. Unlike injected GH peptides, it works orally and lasts about 24 hours per dose.

Effects

ENDOCRINE / GH AXIS [Tier 1 – Human Clinical]: MK-677 (Ibutamoren) is a non-peptide, orally active ghrelin receptor agonist that produces sustained GH and IGF-1 elevation for up to 24 hours from a single oral dose. Phase II trials demonstrated IGF-1 increases of 40-97% from baseline maintained over 12 months of daily use. Unlike injectable GHRPs, MK-677 does NOT desensitize with chronic use — GH and IGF-1 elevation is maintained over months to years. This is its key advantage and differentiator. Peak GH occurs 1-2 hours post-dose, but elevation persists throughout the day. METABOLIC [Tier 1 – Human Clinical]: THE CRITICAL CONCERN: MK-677 significantly impairs insulin sensitivity and raises fasting glucose. Murphy et al. (2001): 2-month treatment increased fasting glucose by 0.3 mmol/L and fasting insulin by 26%. Nass et al. (2008): 12-month study in elderly showed sustained IGF-1 elevation BUT also significant insulin resistance, increased HbA1c, and impaired glucose tolerance. This is the single most important clinical consideration with MK-677 and the primary reason many practitioners limit its use. BODY COMPOSITION [Tier 1 – Human Clinical]: Improves lean body mass and may reduce visceral fat. Nass et al. (2008): Lean body mass increased, fat mass was not significantly reduced. The body composition effects are modest — this is NOT a dramatic fat loss agent. In fact, some patients gain weight (water retention + appetite). SLEEP [Tier 1 – Human Clinical]: Copinschi et al. (1997): MK-677 increased REM sleep duration by 50% and Stage IV slow-wave sleep by 20% in young healthy subjects. This is one of the most consistently reported benefits — profound sleep quality improvement, often noticed within the first week. APPETITE [Tier 1 – Human Clinical]: Robust appetite stimulation in most users. Ghrelin receptor activation drives hunger, especially in the first 4-8 weeks. Some tolerance develops, but many users experience persistent increased appetite throughout use. BONE DENSITY [Tier 1 – Human Clinical]: Murphy et al. (2001): Improved markers of bone turnover. Long-term use may increase bone mineral density through sustained GH/IGF-1 elevation. Particularly relevant for elderly and post-menopausal populations. MUSCULOSKELETAL [Tier 2 – Limited Human]: Indirect anabolic effects through sustained GH/IGF-1. Connective tissue repair, recovery enhancement. Nitrogen retention improved. Not directly anabolic to the degree of exogenous GH, but sustained elevation provides consistent anabolic support. NEUROLOGICAL [Tier 2 – Limited Human]: Sleep architecture improvement well-documented. Some evidence for cognitive benefits (GH/IGF-1 are neuroprotective). Ghrelin receptor activation in hippocampus may enhance memory consolidation. Long-term neuroprotective potential not established.

Practitioner Guide

CLINICAL POSITIONING: MK-677 is the most widely used GH secretagogue in the optimization space due to one overwhelming advantage: it is ORAL and does NOT desensitize. For patients who refuse injections or want long-term GH optimization without cycling, MK-677 is the default choice. However, it comes with significant metabolic trade-offs that MUST be actively managed. DOSING PROTOCOLS: • Starting dose: 10 mg orally once daily. Stay here for 2-4 weeks to assess tolerance and appetite. • Standard optimization: 12.5-25 mg once daily. Most practitioners settle on 12.5-15 mg as the sweet spot (good IGF-1 elevation with manageable side effects). • Aggressive: 25 mg daily. Maximum GH/IGF-1 response but significantly more insulin resistance, water retention, and appetite stimulation. • Timing: PRE-BED is the strongly preferred timing. Reasons: (1) amplifies natural nocturnal GH surge, (2) you sleep through the worst of the hunger, (3) sleep-enhancing effects are maximized. Taking it in the morning causes problematic daytime hunger and lethargy for many users. • With food or without: Can be taken with or without food. Some practitioners recommend taking with a small meal to reduce appetite surge. • Cycling: Not strictly necessary from a desensitization standpoint (MK-677 does not desensitize). However, many practitioners cycle 3 months on / 1 month off to give the metabolic system a break from sustained GH/insulin effects. INSULIN RESISTANCE MANAGEMENT — THE CRITICAL PROTOCOL: This is what separates competent MK-677 prescribing from irresponsible use. • BASELINE LABS (non-negotiable before starting): Fasting glucose, fasting insulin, HbA1c, HOMA-IR calculation. If fasting glucose >100, HbA1c >5.6, or HOMA-IR >2.0 — patient is already insulin-resistant and MK-677 carries elevated risk. Consider alternative GH peptide. • BERBERINE PROTOCOL: Most common practitioner mitigation strategy. - Berberine 500 mg 2-3x daily with meals, started simultaneously with MK-677. - Berberine activates AMPK, improves insulin sensitivity, and reduces fasting glucose — directly counteracts MK-677 metabolic effects. - Efficacy is comparable to metformin (500 mg) for glucose lowering. - GI side effects (diarrhea, cramping) common initially — start at 500 mg once daily and titrate up over 2 weeks. - Dihydroberberine (DHB) is a more bioavailable form with fewer GI effects. 100-200 mg DHB ≈ 500 mg berberine. • METFORMIN PROTOCOL: For patients under physician supervision with confirmed insulin resistance. - Metformin 500-1000 mg daily (extended release preferred for GI tolerance). - More potent insulin-sensitizing effect than berberine. - REQUIRES prescription. Monitor renal function (eGFR). B12 depletion with long-term use. - Some practitioners use metformin 500 mg ER as standard co-prescription with MK-677. • LIFESTYLE INTERVENTIONS: - Reduce refined carbohydrates and sugar — MK-677 impairs glucose disposal, so carb quality matters more than ever. - Resistance training improves insulin sensitivity and synergizes with GH elevation for body composition. - Time-restricted eating (skip breakfast, eat in 8-hour window) can mitigate fasting glucose rise. - Chromium picolinate 200-400 mcg daily — mild insulin sensitizer, minimal risk. - Apple cider vinegar (1-2 tbsp before carb-heavy meals) — modest glucose blunting. • MONITORING SCHEDULE: - Baseline: Fasting glucose, insulin, HbA1c, IGF-1, lipid panel. - 4-week: Fasting glucose and insulin. If fasting glucose >110 or insulin >15, intervene (add/increase berberine or metformin, reduce MK-677 dose, or discontinue). - 8-week: Full panel including HbA1c (will reflect 2-month average glucose). IGF-1 to confirm response. - 12-week: Full panel. Decision point: continue, reduce dose, or cycle off. - Ongoing: Fasting glucose/insulin every 8-12 weeks while on MK-677. MANAGING WATER RETENTION: • Nearly universal in first 2-4 weeks. Can be dramatic (5-10 lbs of water weight). • Reduce sodium intake. Increase water intake (paradoxically helps). • Dandelion root extract (500 mg 2x daily) — mild natural diuretic. • Usually self-resolving by week 4-6 as the body adapts. • If persistent, reduce dose from 25 mg to 12.5 mg. MANAGING APPETITE: • Pre-bed dosing helps enormously — you sleep through peak hunger. • If daytime dosing required: pair with high-protein, high-fiber meal. • Appetite usually attenuates after 4-8 weeks of consistent use. SUPPLEMENT STACK FOR MK-677 OPTIMIZATION: • Berberine 500 mg 2-3x/day (or DHB 100-200 mg 2x/day) — insulin sensitizer • Chromium picolinate 200 mcg/day — glucose support • Magnesium glycinate 400 mg before bed — sleep support, insulin sensitivity • Vitamin D3 5000 IU/day — GH system support (deficiency impairs GH signaling) • Zinc 30 mg/day — supports IGF-1 production, GH signaling WHO SHOULD NOT USE MK-677: • Pre-diabetics or diabetics (fasting glucose >100, HbA1c >5.7) — unless under close physician supervision with metformin. • Active cancer or history of hormone-sensitive cancer (sustained IGF-1 elevation is concerning). • Patients unwilling to do regular blood work. • Those with uncontrolled edema or congestive heart failure (water retention exacerbates). • Patients on blood glucose-lowering medications without physician coordination.

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  MK-677 significantly elevates GH and IGF-1 levels for up to 24 hours per dose. IGF-1 is a potent mitogen that promotes cell proliferation, inhibits apoptosis, and may accelerate tumor growth, angiogenesis, and metastasis.
  Action: Do not use in patients with any active cancer. Cancer survivors should obtain oncologist clearance and have IGF-1 levels monitored.
• hard stop — Pregnancy
  No human safety data during pregnancy. Sustained GH/IGF-1 elevation poses risk to fetal development including macrosomia and metabolic disruption.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Elevated GH/IGF-1 may affect nursing infant. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis compounds are not designed for unsupervised pediatric use. May disrupt normal growth plate physiology and pubertal development.
  Action: Do not provide to individuals under 18.
• requires physician — Diabetes or insulin resistance
  MK-677 has been shown to worsen insulin resistance and increase fasting blood glucose in clinical trials. It antagonizes insulin action via GH-mediated hepatic glucose output. Long-term use can significantly deteriorate glycemic control.
  Action: Requires physician supervision and frequent blood glucose monitoring. HbA1c monitoring every 3 months. Diabetes medication adjustment likely needed. Consider lower doses.
• caution — Congestive heart failure
  MK-677 causes fluid retention and edema due to GH-mediated sodium and water retention. In CHF patients, this fluid overload may worsen cardiac function, increase hospitalizations, and potentially be fatal. A clinical trial in CHF patients was stopped early due to increased heart failure events.
  Action: Avoid in patients with CHF. If used with physician approval, monitor weight, edema, and cardiac function closely. Discontinue if fluid retention worsens.
• caution — Sleep apnea
  GH elevation can worsen obstructive sleep apnea by promoting soft tissue growth in the upper airway. MK-677 also increases appetite and may contribute to weight gain, further exacerbating OSA.
  Action: Monitor sleep quality. Consider sleep study before and during use. CPAP compliance essential. Discontinue if sleep apnea worsens.
• monitor — Peripheral edema or fluid retention
  MK-677 commonly causes dose-dependent edema and water retention. Patients prone to fluid retention (kidney disease, venous insufficiency, on corticosteroids) may experience significant worsening.
  Action: Monitor weight, limb circumference, and edema daily during initiation. Consider lower starting dose. Reduce dose or discontinue if edema is significant.

Evidence

• Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial

  Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO (2008) — Annals of Internal Medicine — PMID: 18981488

  MK-677 25 mg daily for 2 years significantly increased GH and IGF-1 levels to those of healthy young adults. Fat-free mass increased and abdominal visceral fat did not change. Fasting glucose increased and insulin sensitivity decreased, raising metabolic concerns with long-term use.

  strong

• MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism

  Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR (1998) — Journal of Clinical Endocrinology and Metabolism — PMID: 9589658

  MK-677 reversed diet-induced nitrogen wasting in healthy volunteers on caloric restriction. Daily oral administration increased GH pulsatility, IGF-1 levels, and improved nitrogen balance, suggesting potential for counteracting catabolic states without exogenous GH.

  moderate

• Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men

  Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E (1997) — Journal of Clinical Endocrinology and Metabolism — PMID: 9177381

  Seven-day oral MK-677 treatment increased mean 24-hour GH concentrations by 97% and IGF-1 by 55% in healthy young men. GH pulsatility pattern was preserved. Cortisol and PRL levels were transiently elevated but normalized. No significant changes in thyroid function.

  moderate

Stacks featuring this peptide

Research Summary

TIER 1 (Human Clinical Trials): • Nass et al. (2008, Annals of Internal Medicine): 12-month RCT in healthy elderly (n=65). MK-677 25 mg daily restored IGF-1 to young-adult levels (+97%). Increased lean body mass. BUT: significantly increased fasting glucose (+0.3 mmol/L), HbA1c, and insulin resistance. This is the landmark study defining both the promise and the risk. • Murphy et al. (2001, JCEM): 2-month study in obese males. Increased GH, IGF-1, and fat-free mass. Confirmed insulin resistance as primary metabolic concern. • Copinschi et al. (1997, Neuroendocrinology): Demonstrated 50% increase in REM sleep and 20% increase in Stage IV sleep duration. • Chapman et al. (1996): Dose-ranging studies establishing 25 mg as maximum effective oral dose. • NO desensitization: Multiple studies confirmed sustained GH/IGF-1 elevation over 6-12 months without tachyphylaxis. Unique among GH secretagogues. TIER 2 (Limited Human / Strong Preclinical): • Bone density improvement markers with chronic use. • Nitrogen retention studies confirming anabolic support. • Appetite and food intake quantification studies. • Sleep architecture characterization by polysomnography. TIER 3 (Preclinical / Mechanistic): • Non-peptide ghrelin mimetic mechanism — binds GHS-R1a but is structurally distinct from peptide GHRPs. • Oral bioavailability ~60-70%, enabling once-daily oral dosing. • Animal models: Improved wound healing, bone repair, neuroprotection. • IGF-1/cancer epidemiological concern: Sustained IGF-1 elevation above reference range is associated with increased cancer risk in observational studies (not specific to MK-677 but relevant). EVIDENCE GAPS: Never completed Phase III trials (development discontinued by Merck). Optimal dose for long-term optimization not established (most data at 25 mg — may be too high for chronic use). Insulin resistance mitigation strategies (berberine, metformin) not studied in combination with MK-677 in clinical trials. Cancer risk with years of sustained IGF-1 elevation unknown. MK-677 + exercise interaction on insulin sensitivity not formally studied.